Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of SX-682 treatment on gene expressions of three murine cell lines.

ABSTRACT: To identify tumor-specific transcriptional changes following SX-682 treatment, we performed RNA sequencing on each of the MelanA, B16F0, and B16F10 cell lines.

ORGANISM(S): Mus musculus

PROVIDER: GSE223288 | GEO | 2023/06/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

ChIPseq analysis of changes in binding of TFCP2L1 antibody in B16F0 cells in response to SX-682 treatment.

Project description:To define the activity of TFCP2L1 following CXCR2 perturbation, we performed chromatin immunoprecipitation and sequencing analysis (CHIPseq) on B16F0 tumorigenic melanoma cells following treatment with vehicle or SX-682.

2023-06-07 | GSE223289 | GEO

Effect of SX-682 on gene expression for BrafV600E/PTEN-/- mice.

Project description:To evaluate the effect of the dual CXCR1/CXCR2 inhibitor SX-682 on tumor growth, BrafV600E/PTEN-/- mice were fed with either SX-682 chow (0.756 g/kg of SX-682, Syntrix Pharmaceuticals, Inc) or control chow for RNA-seq analysis.

2023-06-07 | GSE223286 | GEO

Effect of CXCL1 and CXCL1 with SX-682 on gene expression for human epidermal melanocytes (NHEM) cells.

Project description:To gain insight into how CXCL1 activation of CXCR2 regulates the expression of stemness and differentiation markers, RNAseq analysis was performed on normal human epidermal melanocyte (NHEM) cultures treated with CXCL1 or with CXCL1 and SX-682.

2023-06-07 | GSE223285 | GEO

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

Project description:This phase Ib/II trial studies the side effects and best dose of SX-682 that can be given alone and in combination with nivolumab in treating patients with RAS-Mutated, microsatellite stable (MSS) colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). SX-682 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 alone and together with nivolumab may kill more tumor cells.

| 2355422 | ecrin-mdr-crc

Single cell 3' RNA sequencing of B16 melanoma (B16F0 and B16F10)

Project description:Under the hypothesis that subset of parental cells may already harbor metastasis potential, which leads progression of metastasis, we investigated single-cell expression of parental B16 melanoma cell (B16F0) and its highly metastatic subclone (B16F10) (N=4,156) using single-cell RNA sequencing

2022-04-10 | GSE156444 | GEO

Identification of endothelial derived factors that promote metastasis II

Project description:To identify endothelial-derived factors that may instructively drive cancer metastasis, we generated a new mouse model that allows endothelial-specific ribosomal tagging. We crossed the RiboTag (Rpl22fl/flHA) mice with the endothelial inducible Cre line Cdh5(PAC)-CreERT2 mice. Endothelial derived ribosome-associated mRNA-sequencing was performed from highly metastatic B16F10 and poorly metastatic B16F0 tumours.

2020-06-29 | GSE145291 | GEO

Identification of endothelial derived factors that promote metastasis III

2020-06-29 | GSE145317 | GEO

Identification of endothelial derived factors that promote metastasis I

2020-06-29 | GSE145293 | GEO

Effect of SIRPA perturbation on transcriptome of B16 murine melanoma cells

Project description:To explore the effect of SIRPA perturbation on the expression changes of melanoma differentiation antigens (MDA), which directly mediates the immunogenicity of melanoma cells, we profiled the transcriptomes of B16F10 cells with SIRPA knockdown, overexpression, or control.

2022-08-18 | GSE211226 | GEO